Dr. Haijun Dong currently serves as Managing Director for DIA China. Dr. Dong brings considerable experience and expertise to DIA and will serve to continue to catalyze DIA’s presence and impact in China, with breadth and depth in the biopharmaceutical industry as well as in academia. Over his distinguished career, Dr. Dong held executive positions as the Chief Operating Officer of Lilly China R&D, a subsidiary of Eli Lily and Company, and with IMPACT Therapeutics, Inc., where he served as President and CEO. Dr. Dong has been employed by Roche both in China and in the US, and other Chinese and international companies serving in R&D, Sales & Marketing, Business Development, and Executive Leadership capacities. Dr. Dong has received a number of awards and recognition in recent years, one of which was for "Leading Talent in Creativity, Innovation and Entrepreneurship" by the National Nanjing High and New Technology Zone and Nanjing University of Technology where he was awarded a full professorship. He has been a frequent speaker in Chinese and international conferences and on university campuses on topics like China strategy for multinational pharmaceutical companies as well as career and life development choices for college students and young professionals. Dr. Dong holds an MBA from the China Europe International Business School and a PhD in Chemistry from the University of Washington, building on his undergraduate training as a chemist.